Cytarabine (ara-C) is the key agent for treating acute myeloid leukemia. After being transported into leukemic cells, ara-C is phosphorylated, by several enzymes including deoxycytidine kinase (dCK), to ara-C triphosphate (ara-CTP), an active metabolite, and then incorporated into DNA, thereby inhibiting DNA synthesis. Therefore, the cytotoxicity of ara-C depends on the production of ara-CTP and the induction of apoptosis. Here, we established a new ara-C-resistant acute myeloid leukemia cell line (HL-60/ara-C60) with dual resistance characteristics of the anti-antimetabolic character of decreased ara-CTP production and an increase in the antiapoptotic factors Bcl-2 and Bcl-XL. We further attempted to overcome resistance by augmenting ara-C...
Autophagy is a lysosomal degradation mechanism that is essential for cell survival, differentiation,...
We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (A...
We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (A...
Cytarabine (ara-C) is the key agent for treating acute myeloid leukemia. After being transported int...
Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overri...
Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overri...
High expression of p26Bcl-2 in patient-derived AML cells has been associated with poor response to c...
Treatment failure in refractory or relapsed disease is often caused by resistance towards Ara-C or d...
1-\u3b2-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myel...
1-β-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myelogen...
1-β-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myelogen...
1-β-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myelogen...
1-β-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myelogen...
Treatment failure in refractory or relapsed disease is often caused by resistance towards Ara-C or ...
The mechanisms underlying acute myeloid leukemia (AML) treatment failure are not clear. Here, we est...
Autophagy is a lysosomal degradation mechanism that is essential for cell survival, differentiation,...
We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (A...
We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (A...
Cytarabine (ara-C) is the key agent for treating acute myeloid leukemia. After being transported int...
Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overri...
Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overri...
High expression of p26Bcl-2 in patient-derived AML cells has been associated with poor response to c...
Treatment failure in refractory or relapsed disease is often caused by resistance towards Ara-C or d...
1-\u3b2-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myel...
1-β-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myelogen...
1-β-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myelogen...
1-β-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myelogen...
1-β-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myelogen...
Treatment failure in refractory or relapsed disease is often caused by resistance towards Ara-C or ...
The mechanisms underlying acute myeloid leukemia (AML) treatment failure are not clear. Here, we est...
Autophagy is a lysosomal degradation mechanism that is essential for cell survival, differentiation,...
We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (A...
We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (A...